DK1689720T3 - Pyrazolyl-derivater i form af medikamenter til behandling af akutte eller kroniske tilstande med neuronal degeneration - Google Patents

Pyrazolyl-derivater i form af medikamenter til behandling af akutte eller kroniske tilstande med neuronal degeneration

Info

Publication number
DK1689720T3
DK1689720T3 DK04805499T DK04805499T DK1689720T3 DK 1689720 T3 DK1689720 T3 DK 1689720T3 DK 04805499 T DK04805499 T DK 04805499T DK 04805499 T DK04805499 T DK 04805499T DK 1689720 T3 DK1689720 T3 DK 1689720T3
Authority
DK
Denmark
Prior art keywords
medications
acute
treatment
chronic conditions
neuronal degeneration
Prior art date
Application number
DK04805499T
Other languages
English (en)
Inventor
Jean-Francois Sabuco
Arielle Genevois-Borella
Jean-Luc Malleron
Jean Bouquerel
Gilles Doerflinger
Andrees Bohme
Gaetan Touyer
Corinne Terrier
Serge Mignani
Michel Evers
Youssef El-Ahmad
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK1689720T3 publication Critical patent/DK1689720T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK04805499T 2003-11-25 2004-11-22 Pyrazolyl-derivater i form af medikamenter til behandling af akutte eller kroniske tilstande med neuronal degeneration DK1689720T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0313775A FR2862647B1 (fr) 2003-11-25 2003-11-25 Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
PCT/FR2004/002968 WO2005051917A1 (fr) 2003-11-25 2004-11-22 Derives de pyrazole a titre de medicaments pour le traitement des degenerescences neuronales aigues ou chroniques

Publications (1)

Publication Number Publication Date
DK1689720T3 true DK1689720T3 (da) 2009-08-10

Family

ID=34531236

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04805499T DK1689720T3 (da) 2003-11-25 2004-11-22 Pyrazolyl-derivater i form af medikamenter til behandling af akutte eller kroniske tilstande med neuronal degeneration

Country Status (31)

Country Link
US (2) US7524838B2 (da)
EP (1) EP1689720B1 (da)
JP (1) JP4833078B2 (da)
KR (1) KR20060123193A (da)
CN (2) CN102174017A (da)
AR (1) AR046632A1 (da)
AT (1) ATE428699T1 (da)
AU (1) AU2004293214B2 (da)
BR (1) BRPI0416926A (da)
CA (1) CA2544519A1 (da)
CY (1) CY1110333T1 (da)
DE (1) DE602004020660D1 (da)
DK (1) DK1689720T3 (da)
ES (1) ES2325446T3 (da)
FR (1) FR2862647B1 (da)
HR (1) HRP20090391T1 (da)
IL (1) IL175539A0 (da)
MA (1) MA28147A1 (da)
MY (1) MY141218A (da)
NO (1) NO20062954L (da)
NZ (1) NZ548071A (da)
PL (1) PL1689720T3 (da)
PT (1) PT1689720E (da)
RS (1) RS50836B (da)
RU (2) RU2376290C2 (da)
SG (1) SG131945A1 (da)
SI (1) SI1689720T1 (da)
TW (1) TWI343811B (da)
UY (1) UY28635A1 (da)
WO (1) WO2005051917A1 (da)
ZA (2) ZA200604051B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3019B1 (ar) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
DK2430921T3 (da) 2007-04-03 2017-10-16 Du Pont Substituerede benzenfungicider
US8183381B2 (en) * 2007-07-19 2012-05-22 Metabolex Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
RU2474579C2 (ru) 2007-10-18 2013-02-10 Янссен Фармацевтика Нв Тризамещенные 1,2,4-триазолы
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
AU2009226988B2 (en) 2008-03-19 2013-05-23 Janssen Pharmaceutica Nv Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators
JP5486591B2 (ja) 2008-05-09 2014-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アセチルコリン受容体モジュレーターとしての三置換ピラゾール
EP2151434A1 (en) 2008-08-05 2010-02-10 Institut Pasteur Alkoxypyrazoles and the process for their preparation
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
CN102574832B (zh) * 2009-09-17 2014-09-24 詹森药业有限公司 取代的n-苯基-1-(4-吡啶基)-1h-吡唑-3-胺
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
ES2676209T3 (es) 2010-06-23 2018-07-17 Metabolex Inc. Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
BR102012024778A2 (pt) * 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
US9126984B2 (en) 2013-11-08 2015-09-08 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
CA2929650C (en) * 2013-11-08 2017-08-22 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
EP3105225A1 (en) 2014-02-12 2016-12-21 iTeos Therapeutics Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
MX2016015005A (es) 2014-05-15 2017-09-28 Iteos Therapeutics Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1.
SG11201705701UA (en) * 2015-02-27 2017-08-30 Toray Industries Cyclic amine derivative and pharmaceutical use thereof
KR102013512B1 (ko) 2015-03-17 2019-08-22 화이자 인코포레이티드 신규 3-인돌 치환 유도체, 제약 조성물 및 사용 방법
EP3334733A1 (en) 2015-08-10 2018-06-20 Pfizer Inc 3-indol substituted derivatives, pharmaceutical compositions and methods for use
KR102625861B1 (ko) * 2016-06-28 2024-01-17 삼성디스플레이 주식회사 헤테로시클릭 화합물 및 이를 포함한 유기 발광 소자
US10292983B2 (en) 2016-08-03 2019-05-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
TWI702210B (zh) * 2016-08-26 2020-08-21 日商東麗股份有限公司 環狀胺衍生物之結晶及其醫藥用途
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2021110574A1 (en) * 2019-12-02 2021-06-10 F. Hoffmann-La Roche Ag Alkynyl-(heteroaryl)-carboxamide hcn1 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2014831A1 (en) 1968-08-01 1970-04-24 Sogeras Quinuclidinyl and quinuclidinylalkyl ethers with cholino - lytic, antihistaminic and neurosedative activity
EP0427390B1 (en) * 1989-10-07 1996-03-27 Beecham Group Plc Azabicyclic compounds, process and intermediates for their preparation and pharmaceutical compositions containing them
WO1992021339A1 (en) * 1991-05-29 1992-12-10 Abbott Laboratories Isoxazole and isothiazole compounds that enhance cognitive function
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
GB9500580D0 (en) * 1995-01-12 1995-03-01 Merck Sharp & Dohme Therapeutic agents
EP1002871A1 (en) 1998-11-17 2000-05-24 Eidgenössische Technische Hochschule (ETH) Zürich Process for preparing optically active 3-hydroxy-pyrrolidine derivatives by enzymatic hydroxylation
FR2786188B1 (fr) * 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS

Also Published As

Publication number Publication date
MA28147A1 (fr) 2006-09-01
US8048893B2 (en) 2011-11-01
JP4833078B2 (ja) 2011-12-07
RU2376290C2 (ru) 2009-12-20
UY28635A1 (es) 2005-06-30
CN102174017A (zh) 2011-09-07
BRPI0416926A (pt) 2007-01-16
JP2007536213A (ja) 2007-12-13
ATE428699T1 (de) 2009-05-15
ES2325446T3 (es) 2009-09-04
KR20060123193A (ko) 2006-12-01
EP1689720B1 (fr) 2009-04-15
CN1906172A (zh) 2007-01-31
FR2862647A1 (fr) 2005-05-27
RU2009122368A (ru) 2010-12-20
ZA200706854B (en) 2008-09-25
US20090170833A1 (en) 2009-07-02
SI1689720T1 (sl) 2009-08-31
ZA200604051B (en) 2007-12-27
TWI343811B (en) 2011-06-21
MY141218A (en) 2010-03-31
PT1689720E (pt) 2009-07-20
US20050165005A1 (en) 2005-07-28
SG131945A1 (en) 2007-05-28
AR046632A1 (es) 2005-12-14
IL175539A0 (en) 2006-09-05
AU2004293214B2 (en) 2011-04-21
PL1689720T3 (pl) 2009-09-30
CY1110333T1 (el) 2015-01-14
WO2005051917A1 (fr) 2005-06-09
RU2006122553A (ru) 2008-01-10
CA2544519A1 (fr) 2005-06-09
NZ548071A (en) 2010-03-26
US7524838B2 (en) 2009-04-28
WO2005051917A9 (fr) 2005-09-29
EP1689720A1 (fr) 2006-08-16
NO20062954L (no) 2006-08-25
HRP20090391T1 (en) 2009-08-31
RS50836B (sr) 2010-08-31
AU2004293214A1 (en) 2005-06-09
TW200529826A (en) 2005-09-16
FR2862647B1 (fr) 2008-07-04
DE602004020660D1 (de) 2009-05-28
WO2005051917B1 (fr) 2005-08-04

Similar Documents

Publication Publication Date Title
DK1689720T3 (da) Pyrazolyl-derivater i form af medikamenter til behandling af akutte eller kroniske tilstande med neuronal degeneration
DK1765322T3 (da) Retinal-derivater og fremgangsmåder til anvendelse deraf i behandlingen af synsforstyrrelser
DK1771191T3 (da) Præparat til anvendelse af aspartat og B12-vitamin eller biotin til regulering af ketonstoffer
DK2430022T3 (da) 1,2,4-Triazolo[4,3-a]pyridinderivater og deres anvendelse til behandlingen eller forebyggelse af neurologiske og psykiatriske lidelser
DK2155758T3 (da) Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
DK1928886T3 (da) Pyridin-derivater og deres anvendelse i behandlingen af psykotiske lidelser
DK1911756T3 (da) Substituerede pyridinyl- og pyrimidinylderivater som modulatorer af metabolisme og behandling af forstyrrelser relateret dertil
NO20054905D0 (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
DK2292617T3 (da) 1,3-Dihydro-imidazo[4,5-c]quinolin-2-ones som lipid kinase og/eller pi3-kinase-inhibitorer
IL192470A0 (en) Anthranilamide derivatives and their use for the control of insects and acari
MA29039B1 (fr) Dibenzylamines et derives
GB2423606B (en) System-on-chip having adjustable voltage level and method for the same
DE502004002864D1 (de) Mikrostruktur mit kerbentlastung
DE602005023884D1 (de) Wässrige grundierungszusammensetzung, oberflächenbehandlungsverfahren unter verwendung derselben und mehrschichtige struktur
BRPI0719877A2 (pt) Elementos de engaxetamento randômicos e coluna contendo os mesmos
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
ATE525919T1 (de) Bouillon- oder würzkonzentrat und verfahren zu dessen herstellung
FI20050225A (fi) Primerointi- ja päällystysprosessi
DK2012816T3 (da) Anvendelse af Thymosin 1, alene eller i kombination med PTX3 eller Ganciclovir, til behandling af Cytomegalovirus infektion.
ATE446760T1 (de) Verwendung von nichtsteroidalen entzündungshemmern bei der behandlung von akuter und chronischer bronchitis
DK1912513T3 (da) Hidtil ukendte mælkeproteinfraktioner og anvendelse deraf til forebyggelse eller behandling af kroniske inflammatoriske sygdomme
DK2193789T3 (da) Anvendelse af 3,5-dihydroxytoluen eller derivater deraf i fremstillingen af medicin og funktionelle fødevarer til behandling eller forebyggelse af depression
DK1545553T3 (da) Anvendelse af alkylphosphocholiner i kombination med antitumormedikamenter
BRPI0714307A2 (pt) Uso de benzamidas trifluormetil-substituídas no tratamento de distúrbios neurológicos
FI20055684A (fi) Menetelmä taajuusmuuttajan yhteydessä ja taajuusmuuttaja